Novavax (NVAX) Other Operating Expenses (2011 - 2026)
Novavax (NVAX) posted quarterly Other Operating Expenses of $30.7 million for Q1 2026, up 117.46% year-over-year from $14.1 million in Q1 2025, and up 33.97% quarter-over-quarter from $22.9 million in Q4 2025.
Novavax (NVAX) Other Operating Expenses (2011 - 2026) Analysis & Trends
Novavax's Other Operating Expenses history runs 10 years deep, the most recent figure standing at $30.7 million for Q1 2026.
- In Q1 2026, Other Operating Expenses rose 117.46% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $187.5 million (up 18.92% YoY), while the FY2024 annual figure was $51.9 million, changed N/A from the prior year.
- Other Operating Expenses for Q1 2026 stood at $30.7 million, up from $22.9 million in the prior quarter.
- The five-year high for Other Operating Expenses was $434.6 million in Q3 2022, with the low at $14.1 million in Q1 2025.
- The 5-year median for Other Operating Expenses is $55.8 million (2023), against an average of $97.1 million.
- Peak annual rise in Other Operating Expenses reached 124.19% in 2023, while the deepest fall reached 79.42% in 2023.
- Novavax's Other Operating Expenses stood at $181.8 million in 2022, then slipped by 14.74% to $155.0 million in 2023, then plunged by 76.34% to $36.7 million in 2024, then tumbled by 37.52% to $22.9 million in 2025, then jumped by 33.97% to $30.7 million in 2026.
- Business Quant data shows NVAX's Other Operating Expenses at $30.7 million in Q1 2026, $22.9 million in Q4 2025, and $118.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.25 Mn |
| Mar 31, 2026 | 30.70 Mn |
| Dec 31, 2025 | 22.91 Mn |
| Sep 30, 2025 | 118.53 Mn |
| Jun 30, 2025 | 15.33 Mn |
| Mar 31, 2025 | 14.12 Mn |
| Dec 31, 2024 | 36.67 Mn |
| Sep 30, 2024 | 60.62 Mn |
| Jun 30, 2024 | 46.24 Mn |
| Mar 31, 2024 | 59.21 Mn |
| Dec 31, 2023 | 154.98 Mn |
| Sep 30, 2023 | 98.93 Mn |
| Jun 30, 2023 | 55.78 Mn |
| Mar 31, 2023 | 34.09 Mn |
| Dec 31, 2022 | 181.77 Mn |
| Sep 30, 2022 | 434.59 Mn |
| Jun 30, 2022 | 271.08 Mn |
| Mar 31, 2022 | 15.20 Mn |
| Sep 30, 2019 | 9.02 Mn |
| Dec 31, 2014 | -12.15 Mn |